Could a lower dose of a harsh transplant drug be just as safe?
NCT ID NCT06705062
Summary
This study aims to find out if a lower dose of a key drug (cyclophosphamide) given after a stem cell transplant works as well as the standard dose to prevent graft-versus-host disease (GVHD). It will involve 316 patients receiving transplants from donors who are not a perfect match. The goal is to control the disease while potentially reducing side effects from the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT -VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Ruijin hsopital
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.